Safety and regulatory issues in anabolic agents' use and development.
Malozowski
S
S
Division of Endocrine and Metabolic Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA.
Koller
E
E
D002100:Cachexia / Q000188:drug therapy; D006133:Growth Substances / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007880:Legislation, Drug
D006133:Growth Substances